首页> 美国卫生研究院文献>The Journal of Biological Chemistry >UL52 Primase Interactions in the Herpes Simplex Virus 1 Helicase-Primase Are Affected by Antiviral Compounds and Mutations Causing Drug Resistance
【2h】

UL52 Primase Interactions in the Herpes Simplex Virus 1 Helicase-Primase Are Affected by Antiviral Compounds and Mutations Causing Drug Resistance

机译:抗病毒化合物和引起耐药性的突变会影响单纯疱疹病毒1解旋酶-Primase中的UL52酶相互作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Herpes simplex virus 1 (HSV-1) UL5/8/52 helicase-primase complex is required for DNA unwinding at the replication fork and synthesis of primers during virus replication, and it has become a promising novel target for antiviral therapy. Using molecular cloning, we have identified three separate domains of UL52. Co-immunoprecipitation experiments in extracts from cells transiently expressing HA-tagged UL5, FLAG-UL8, and enhanced GFP-tagged UL52 domains revealed that the N-terminal domain of UL52 primase binds UL5 helicase and the middle domain interacts with the UL8 accessory protein. In addition, an interaction between the single strand DNA-binding protein ICP8 and the UL52 middle domain was observed. The complex between UL5 and UL52 was stabilized by the antiviral compound BAY 54-6322, and mutations providing resistance to the drug obliterate this effect. Our results also suggest a mechanism for accommodating conformational strain resulting from movement of UL5 and UL52 in opposite directions on the lagging strand template, and they identify molecular complexes that can be further examined by structural biology techniques to resolve the mechanism of primer synthesis during herpesvirus replication. Finally, they help to explain the mechanism of action of a novel class of antiviral compounds currently being evaluated in clinical trials.
机译:单纯疱疹病毒1(HSV-1)UL5 / 8/52解旋酶-引发酶复合物是在复制叉上展开DNA并在病毒复制过程中合成引物所必需的,它已成为抗病毒治疗的新靶标。使用分子克隆,我们确定了UL52的三个独立域。在瞬时表达HA标记的UL5,FLAG-UL8和增强的GFP标记的UL52结构域的细胞提取物中的共免疫沉淀实验表明,UL52 primase的N末端结构域与UL5解旋酶结合,中间结构域与UL8辅助蛋白相互作用。另外,观察到单链DNA结合蛋白ICP8和UL52中间结构域之间的相互作用。 UL5和UL52之间的复合物被抗病毒化合物BAY 54-6322稳定,对药物产生抗性的突变消除了这种作用。我们的研究结果还提出了适应机制,以适应由UL5和UL52在滞后链模板上相反方向移动引起的构象菌株,并且他们鉴定了可以通过结构生物学技术进一步检查以解决疱疹病毒复制过程中引物合成机理的分子复合物。 。最后,它们有助于解释目前正在临床试验中评估的新型抗病毒化合物的作用机理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号